Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 14

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 14
---
787,703  
     -  
     787,703  
     - 
  
    Net
    loss 
    $5,228,919  
    $4,015,267  
    $9,761,349  
    $7,821,944 

NOTE
10: SUBSEQUENT EVENTS

The
Company evaluated subsequent events from June 30, 2025, the date of these unaudited condensed consolidated financial statements, through
August 13, 2025, which represents the date the condensed consolidated financial statements were issued, for events requiring recognition
or disclosure in the condensed consolidated financial statements for the six months ended June 30, 2025. The Company concluded that no
events have occurred that would require recognition or disclosure in the condensed consolidated financial statements except for the conversion
of the Notes on July 27, 2025 and the related issuance of the July 2025 Warrants and placement agent warrants, as described in Note 7
above. As a result of the conversion of the Notes on July 27, 2025, the Company classified the fair value of the Notes
from current liabilities to shareholders’ equity. Therefore, as of the date hereof, the Company believes that it satisfies the minimum
shareholders’ equity requirement of $2.5 million under Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital
Market.

F-12

Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Unless
the context indicates otherwise, in this Quarterly Report, the terms “Indaptus,” “the Company,” “we,”
“us” and “our” refer to Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc., the successor of Intec Pharma
Ltd. following the domestication merger) and, where appropriate, its consolidated subsidiaries following the domestication merger and
the reverse merger described in our previous periodic reports. References to “Intec Israel” refer to Intec Pharma Ltd., the
predecessor of Indaptus prior to the domestication merger, and references to “Decoy” refer to Decoy Biosystems, Inc., the
entity acquired by Indaptus in connection with the reverse merger.

You
should read the following discussion and analysis of our financial condition and results of operations along with our consolidated financial
statements and the related notes and other financial information included elsewhere in this Quarterly Report and